MCMichael J. Clemente

Michael J. Clemente

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael J. Clemente has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sex Influences Age-Related Changes in Natural Antibodies and CD5+ B-1 Cells

    by Sarah E Webster, Brinda Ryali, Michael J. Clemente, Naomi L. Tsuji, Nichol E Holodick

    Natural Abs are primarily produced by B-1 cells and are essential for protection against Streptococcus pneumoniae. The incidence and mortality rate for pneumococcal infection increases dramatically after age 65, disproportionately affecting males in both human and murine systems. To date, there is a significant gap in our understanding of the relationship among sex, aging, natural IgM efficacy, and the natural IgM repertoire. Our investigation demonstrates that the protective capacity of serum IgM against pneumococcal infection is maintained in IgM obtained from aged female mice but absent in IgM from aged male mice. To understand this difference in protective capacity, we examined serum Ig, discovering that the protective change was not associated with shifts in levels of phosphorylcholine (PC)- or pneumococcal capsular polysaccharide serotype 3–specific IgM. Interestingly, we observed that aged females have an increase in the total number of CD5+ B-1 cells, higher serum IL-5 levels, and a larger percentage of aged female CD5+ B-1 cells that express CD86 as compared with aged males. Furthermore, single-cell IgM repertoire analysis from peritoneal PC+, splenic PC+, and bone marrow CD5+ B-1 cell subsets demonstrated greater diversity with age and a higher level of germline status in female mice than previously observed in studies of aged male mice. Aged female CD5+ B-1 cells also expressed higher levels of transcripts associated with cell activity and self-renewal, such as Nanog and Hmga2. Taken together, these data indicate that females maintain a more diverse and active CD5+ B-1 cell pool and natural IgM repertoire, which has implications for sex-related susceptibility to infection and disease.


  • Open Access

    Subclonal STAT3 mutations solidify clonal dominance

    by Cassandra M. Kerr, Michael J. Clemente, Peter W. Chomczynski, Bartlomiej Przychodzen, Yasunobu Nagata, Vera Adema, Valeria Visconte, Alan E. Lichtin, Satu Mustjoki, Tomas Radivoyevitch, et al.

    T large granular lymphocyte leukemia (T-LGLL) is a clonal lymphoproliferative disorder that can arise in the context of pathologic or physiologic cytotoxic T-cell (CTL) responses. STAT3 mutations are often absent in typical T-LGLL, suggesting that in a significant fraction of patients, antigen-driven expansion alone can maintain LGL clone persistence. We set out to determine the relationship between activating STAT3 hits and CTL clonal selection at presentation and in response to therapy. Thus, a group of patients with T-LGLL were serially subjected to deep next-generation sequencing (NGS) of the T-cell receptor (TCR) Vβ complementarity-determining region 3 (CDR3) and STAT3 to recapitulate clonal hierarchy and dynamics. The results of this complex analysis demonstrate that STAT3 mutations produce either a sweeping or linear subclone within a monoclonal CTL population either early or during the course of disease. Therapy can extinguish a LGL clone, silence it, or adapt mechanisms to escape elimination. LGL clones can persist on elimination of STAT3 subclones, and alternate STAT3-negative CTL clones can replace therapy-sensitive CTL clones. LGL clones can evolve and are fueled by a nonextinguished antigenic drive. STAT3 mutations can accelerate this process or render CTL clones semiautonomous and not reliant on physiologic stimulation. Key Points TCR clones can be followed throughout the disease course with deep NGS sequencing of the TCR Vβ CDR3 and STAT3. Visual Abstract


  • Myeloid Cancer Mutation Rates Depend on Prior Cancer Therapies

    by T. Radivoyevitch, T. Kuzmanovic, S. Sanikommu, C. Hirsch, O. Abdel-Hamid, B. Przychodzen, M. Clemente, B. Jha, D. Lindner, R. Moolenaar, et al.

  • Open Access

    The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

    by Xiaorong Gu, Reda Z. Mahfouz, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, M.S. Michael J. Clemente, Bartlomiej P Przychodzen, Zhenbo Hu, Ramesh Balusu, Claudiu V. Cotta, et al.

    Acute myeloid leukemia (AML) is self-renewal by immature myeloid precursors that fail to differentiate. An influential 'leukemia stem cell' model thus proposes that leukemogenic proteins augment or introduce a stem cell-like self-renewal program into cells, e.g., by upregulating signaling or transcription factors (TF) emblematic of stem cells (e.g., HOX). We investigated how the most recurrently mutated protein in AML, mutant nucleophosmin (mNPM1), causes leukemic cell expansion. The results challenge this model, but most importantly, open the door to rational targeted therapy for mNPM1 AML. One way of examining for stem cell programs in AML cells is to look at expression patterns of master TF that regulate expression of hundreds of genes and dictate cell fates. Of these select TF, the master TF that create hematopoietic stem cells (HLF etc.) are minimally or not expressed. Instead, there are very high levels of the master TF that drive monocyte and granulocyte lineage fates, PU.1 (SPI1) and CEBPA. Clearly, however, the lineage-programs intended by PU.1/CEBPA are inefficiently executed if at all - mNPM1 AML patient bone marrows had 85-97% cells with a granulocyte-monocyte progenitor phenotype, accumulated at the expense of downstream mature cells (Quek et al, JEM 2016). This aggregation at a lineage-committed, intermediate, naturally proliferative level of the hematopoietic hierarchy suggests an alternative model - instead of introducing a poorly-defined stem cell self-renewal program, mutant proteins disable differentiation programs which usually quench MYC-driven proliferation intrinsic to lineage-progenitors. To better understand how mNPM1 interacts with cellular machinery, we used mass-spectrometry to comprehensively document the protein interactions of endogenous NPM1 in AML cell nuclear and cytoplasmic fractions, the first analysis of this kind. Notably, the NPM1 protein interactome was enriched for PU.1. Critically, wild-type (wt) NPM1/PU.1 was in the nucleus of wtNPM1 AML cells, but mNPM1/PU.1 was in the cytoplasm of mNPM1 AML cells. This was evident clearly also by Western blot of cell fractions and by IF microscopy of primary AML cells and cell lines. Is cytoplasmic dis-location of PU.1 sufficient to explain persistent hematopoietic precursor proliferation? We used murine Pu.1 knock-out hematopoietic precursors transduced to express Pu.1 fused with the estrogen receptor (Pu.1-ER) to answer this question - Pu.1 relocation from the cytoplasm to the nucleus by tamoxifen triggered monocytic differentiation that terminated proliferation. Moreover, Pu.1-ER cells, like mNPM1 AML cells, highly express Hox genes, rapidly suppressed upon Pu.1 relocation to the nucleus. Thus, Pu.1 dominantly controls Hox and proliferation, as befitting of a master TF, and persistent HOX expression, like persistent progenitor proliferation, can be caused by Pu.1 loss-of-function. Protein macromolecules like NPM1 require transport factors to exit (exportins) the nucleus. A specific exportin, XPO1, was the major exportin found in the NPM1 interactome. XPO1 interactions with transported cargo can be inhibited by the small molecule drug KPT330. KPT330 10-20 nM rapidly re-located mNPM1 and PU.1 to the nucleus, downregulated MYC, upregulated p27/CDKN1B, upregulated monocyte but not granulocyte differentiation markers, induced morphologic changes of monocyte differentiation, and terminated proliferation of mNPM1 AML cells. The same low nanomolar treatment did not induce differentiation of wtNPM1 AML cells (THP1). Moreover, these KPT330 levels are not toxic to normal hematopoiesis (also shown by others). Thus, rather than gain-of-function of elusive stem cell-like self-renewal, the most frequently mutated protein in AML creates self-renewal by disabling a differentiation program that quenches intrinsic MYC-driven proliferation of lineage-progenitors. These observations are a mechanistic rationale to select refractory/relapsed mNPM1 AML patients for treatment with low well-tolerated doses of KPT330, with a defined molecular pharmacodynamic objective of returning PU.1 to the nucleus, to produce cell cycle exits by differentiation rather than p53-mediated apoptosis (to address chemotherapy resistance), to spare precious normal HSC (good therapeutic index), and directly reverse the basis for leukemic self-renewal (proliferation without differentiation).


  • Open Access

    Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria.

    by Christine L. O'Keefe, Chiharu Sugimori, Manuel Afable, Michael Clemente, Kenneth Shain, David Araten, Alan F. List, P.K. Epling-Burnette, Jaroslaw Maciejewski

    Abstract 1158 Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a global deficiency of glycosylphospatidyl inositol-floated proteins (GPI-AP) on the membrane of all cell types derived from the affected stem cell. While the PNH phenotype is non-malignant, outgrowth of GPI-AP (-) clones is mediated by a selective advantage in the context of a permissive condition, such as autoimmune-mediated bone marrow suppression as seen in aplastic anemia (AA). The GPI-AP (-) phenotype results from mutations of the PIG-A gene, located at Xp22.2, which participates in GPI synthesis. Because the gene is X-linked, a single frame-shift or missense inactivating mutation results in loss of enzyme function resulting in GPI-AP deficiency on the cell surface. Due to × chromosome inactivation, the frequency of PNH is similar in men and women. New cytogenetic technologies such as single nucleotide polymorphism array (SNP-A)-based karyotyping show superb resolution allowing for detection of submicroscopic chromosomal defects not seen on metaphase karyotyping. We applied this technology to identify clonal aberrations in patients with PNH (N=32). The average size of the PNH by percentage of CD55/CD59 double negative granulocytes was 73%. Among this cohort, we identified 3 patients with a clonal GPI (-) hematopoietic cell population resembling canonical PNH, but who did not harbor an identifiable mutation in PIG-A. Patients had classic symptoms of hemolysis and fairly typical clinical course. By quantitative PCR, these patients also lacked expression of PIG-A. During this molecular screen, a microdeletion of Xp22.2 encompassing the PIG-A locus, was found in GPI (-) sorted myeloid cells in these 3 patients using GPI (+) T cells as the comparator. This finding underscores the acquired somatic nature of this deletion in these patients. The deletions were 555kb, 506kb and 616kb in length. A commonly deleted region (CDR) of 437kb included PIGA as well seven known neighboring genes (ASB9, ASB11, FIGF, PIR, BMX, ACE2, and TMEM27) and predicted LOC100288981. One patient with the Xq22.2 deletion also had copy neutral loss of heterozygosity (CN-LOH) encompassing 9p24.3p21.3; the JAK2 V617F mutation was found in this patient. One of the remaining 29 patients had trisomy 8, 9 and 21, suggesting a concurrent diagnosis of myelodysplastic syndrome. The PNH phenotype in the male patients (N=2) is easily explained by a hemizygous deletion of the X-linked PIG-A gene. However, in the female patient, the deletion must have occurred on the active (un-lyonized) × chromosome leading to loss of PIG-A transcription and thereby GPI (-) clonal expansion. Nested PCR reactions were performed to amply individual exons of the PIG-A gene and the presence of a wild-type PIG-A gene on the inactive × chromosome was verified by exon amplification, cloning, and sequencing. Our observation indicates that in addition to mutations, the PNH phenotype may arise from an alternate molecular mechanism, namely a segmental chromosomal deletion involving the PIGA locus in addition to inactivating mutations. While three instances of small intragenic deletions, including 2PIGA. This clonal deletion of chromosomal material likely leads to the same selective clonal advantage as hypomorphic mutation of the PIG-A gene.